Mycosis Fungoides — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for mycosis fungoides. 48 active patents protecting 4 drugs from 2+ originators. First major cliff: 2032. Daily refresh.

4
Approved drugs
48
Active US patents
59/100
Avg vulnerability
$1.0B
Annual revenue covered

Originators in Mycosis Fungoides

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Schering) 33 patents Baxter 15 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating mycosis fungoides. Each bar = one year. Y-axis scaled to peak year (9 patents).

5
27
2
28
2
30
5
32
4
33
7
34
9
35
7
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cytoxan (Lyophilized)
cyclophosphamide
 Baxter 15 49 $1.0B 2035-06-26
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8168218 Deltasone method of use 80 2028-01-07
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
11904046 Cortef method of use 75 2043-02-23
12133914 Cortef method of use 75 2043-02-23
8101582 Decadron method of use 63 2027-12-19
7795316 Decadron method of use 63 2028-08-03
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
10022502 Decadron method of use 45 2034-06-22

Related